BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets
Cash and cash equivalents	$ 66,886	$ 130,101
Marketable securities, short-term	176,636	47,504
Prepaid expenses and other current assets	3,093	2,724
Total current assets	246,615	180,329
Marketable securities, long-term	62,553	15,837
Restricted cash	233	0
Property and equipment, net	122	165
Right-of-use asset	381	105
Other assets	221	151
Total assets	310,125	196,587
Current liabilities
Accounts payable	1,379	1,640
Accrued clinical trial expenses	4,387	2,717
Accrued expenses and other current liabilities	6,339	3,350
Finance lease liability, short-term	756	0
Operating lease liability, short-term	110	105
Total current liabilities	12,971	7,812
Operating lease liability, long-term	284	0
Debt, long-term	29,897	0
Total liabilities	43,152	7,812
Commitments and contingencies (Note 11)
Stockholders’ equity
Preferred stock, $0.0001 par value; 10,000,000 shares authorized and no shares issued and outstanding as of December 31, 2023 and 2022	0	0
Common stock, $0.0001 par value; 300,000,000 shares authorized as of December 31, 2023 and 2022; 57,910,461 and 41,025,062 shares issued and outstanding as of December 31, 2023 and 2022, respectively	6	4
Additional paid-in capital	489,453	359,949
Accumulated deficit	(222,798)	(170,427)
Accumulated other comprehensive income (loss)	312	(751)
Total stockholders’ equity	266,973	188,775
Total liabilities and stockholders’ equity	$ 310,125	$ 196,587